These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 39300112)

  • 1. High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma.
    Pishas KI; Cowley KJ; Llaurado-Fernandez M; Kim H; Luu J; Vary R; Bowden NA; Campbell IG; Carey MS; Simpson KJ; Cheasley D
    Sci Data; 2024 Sep; 11(1):1024. PubMed ID: 39300112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
    Hollis RL; Elliott R; Dawson JC; Ilenkovan N; Matthews RM; Stillie LJ; Oswald AJ; Kim H; Llaurado Fernandez M; Churchman M; Porter JM; Roxburgh P; Unciti-Broceta A; Gershenson DM; Herrington CS; Carey MS; Carragher NO; Gourley C
    Gynecol Oncol; 2024 Jul; 186():42-52. PubMed ID: 38582027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
    Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
    Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review.
    Lazurko C; Linder R; Pulman K; Lennox G; Feigenberg T; Fazelzad R; May T; Zigras T
    Curr Oncol; 2023 Sep; 30(9):8159-8171. PubMed ID: 37754507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in precision therapy of low-grade serous ovarian cancer: A review.
    Wang Q; Cao SH; Li YY; Zhang JB; Yang XH; Zhang B
    Medicine (Baltimore); 2024 Apr; 103(17):e34306. PubMed ID: 38669365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.
    Llaurado Fernandez M; Hijmans EM; Gennissen AMC; Wong NKY; Li S; Wisman GBA; Hamilton A; Hoenisch J; Dawson A; Lee CH; Bittner M; Kim H; DiMattia GE; Lok CAR; Lieftink C; Beijersbergen RL; de Jong S; Carey MS; Bernards R; Berns K
    Mol Cancer Ther; 2022 Dec; 21(12):1862-1874. PubMed ID: 36198031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
    Lazurko C; Clark M; Pulman K; Lennox G; May T; Fazelzad R; Gien LT; Zigras T
    Gynecol Oncol; 2021 Oct; 163(1):209-214. PubMed ID: 34325937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-grade serous ovarian carcinoma: A comprehensive literature review.
    Goulding EA; Simcock B; McLachlan J; van der Griend R; Sykes P
    Aust N Z J Obstet Gynaecol; 2020 Feb; 60(1):27-33. PubMed ID: 31849044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum.
    Grisham RN; Chui MH
    Curr Oncol Rep; 2022 Nov; 24(11):1549-1555. PubMed ID: 35962920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.
    Huang TT; Brill E; Nair JR; Zhang X; Wilson KM; Chen L; Thomas CJ; Lee JM
    Cancer Res; 2020 Dec; 80(23):5380-5392. PubMed ID: 32998994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
    Silberman JN; Bercow AS; Gockley AA; Eisenhauer EL; Sisodia R; Randall T; Del Carmen MG; Goodman A; Castro CM; Melamed A; Bregar AJ
    Gynecol Oncol; 2023 Aug; 175():60-65. PubMed ID: 37327540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-grade Serous Tumors: Are We Making Progress?
    Pauly N; Ehmann S; Ricciardi E; Ataseven B; Bommert M; Heitz F; Prader S; Schneider S; du Bois A; Harter P; Baert T
    Curr Oncol Rep; 2020 Jan; 22(1):8. PubMed ID: 31989304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma.
    Voutsadakis IA
    Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():172-178. PubMed ID: 33246201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
    Mert I; Chhina J; Allo G; Dai J; Seward S; Carey MS; Llaurado M; Giri S; Rattan R; Munkarah AR
    Gynecol Oncol; 2017 Aug; 146(2):319-326. PubMed ID: 28545687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
    Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
    J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
    McNamara B; Demirkiran C; Hartwich TMP; Bellone S; Manavella D; Mutlu L; Greenman M; Zipponi M; Yang-Hartwich Y; Yang K; Ratner E; Schwartz PE; Coma S; Pachter JA; Santin AD
    Gynecol Oncol; 2024 Apr; 183():133-140. PubMed ID: 38493021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
    Murumägi A; Ungureanu D; Khan S; Arjama M; Välimäki K; Ianevski A; Ianevski P; Bergström R; Dini A; Kanerva A; Koivisto-Korander R; Tapper J; Lassus H; Loukovaara M; Mägi A; Hirasawa A; Aoki D; Pietiäinen V; Pellinen T; Bützow R; Aittokallio T; Kallioniemi O
    Br J Cancer; 2023 Feb; 128(4):678-690. PubMed ID: 36476658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome.
    Clifford C; Vitkin N; Nersesian S; Reid-Schachter G; Francis JA; Koti M
    Am J Reprod Immunol; 2018 Aug; 80(2):e12975. PubMed ID: 29781548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of uterine involvement in low grade serous ovarian carcinoma.
    Petiot F; Descargues P; Devouassoux-Shisheboran M; You B; Rousset-Jablonski C; Raffin D; Hajri T; Gertych W; Glehen O; Philip CA; Lamblin G; Golfier F; Bolze PA
    Eur J Obstet Gynecol Reprod Biol; 2024 Mar; 294():191-197. PubMed ID: 38295707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.